Thoracic Surgery Intercostal Block Trial With Liposomal vs. Hydrochloride Bupivacaine

This randomized controlled trial evaluates the analgesic effects of liposomal bupivacaine compared to bupivacaine hydrochloride in intercostal nerve block for patients undergoing thoracoscopic lung surgery. Postoperative pain remains a significant issue in thoracic procedures, often leading to complications like pneumonia or delayed recovery. The investigators hypothesize that liposomal bupivacaine, with its extended-release properties, will provide superior pain relief beyond 24 hours compared to standard bupivacaine or no block. Participants will be randomized 1:1:1 to liposomal bupivacaine group , bupivacaine hydrochloride group , or control group . Primary outcome is the area under the curve of pain scores from 25-72 hours post-surgery. Secondary outcomes include opioid consumption, recovery quality (QoR-15), and other complications.

NCT Number	NCT07134660
Lead Sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Conditions	Postoperative Pain, Acute, Lung Cancer
Enrollment	210 participants
Start Date	2025-09-01
Primary Completion	2026-09-15 (estimated)
Study Completion	2026-09-20 (estimated)
Updated on ClinicalTrials.gov	2026-03-30